Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

The prevalence of atrial fibrillation (AF) is related to age. Anticoagulation is highly effective in preventing stroke in patients with AF, but the risk of hemorrhage may be increased in older patients. We reviewed the available epidemiologic data to define the age and sex distribution of people with AF. From four large recent population-based surveys, we estimated the overall age- and gender-specific prevalence of AF. These estimates were applied to the recent US census data to calculate the number of men and women with AF in each age group. There are an estimated 2.2 million people in the United States with AF, with a median age of about 75 years. The prevalence of AF is 2.3% in people older than 40 years and 5.9% in those older than 65 years. Approximately 70% of individuals with AF are between 65 and 85 years of age. The absolute number of men and women with AF is about equal. After age 75 years, about 60% of the people with AF are women. In contrast to people with AF in the general population, patients with AF in recent anticoagulation trials had a mean age of 69 years, and only 20% were older than 75 years. The risks and benefits of antithrombotic therapy in older individuals are important considerations in stroke prevention in AF.

[1]  D L Rosman,et al.  Atrial fibrillation and mortality in an elderly population. , 1989, Australian and New Zealand journal of medicine.

[2]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[3]  E. Campion.  The oldest old. , 1994, The New England journal of medicine.

[4]  J. Halperin,et al.  Atrial fibrillation and stroke. Revisiting the dilemmas. , 1994, Stroke.

[5]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[6]  J. Gardin,et al.  Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). , 1994, The American journal of cardiology.

[7]  J. Halperin,et al.  Aspirin in elderly atrial fibrillation patients. , 1994, Stroke.

[8]  S. Connolly,et al.  Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.

[9]  R. Frye,et al.  Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. , 1990, Mayo Clinic proceedings.

[10]  José A. Aguiñaga.  Statistical abstract of the United States 1993 , 1994 .

[11]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[12]  J. Hill,et al.  Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. , 1987, The Journal of the Royal College of General Practitioners.

[13]  J. I. Bell,et al.  Effect of heparin on polymerase chain reaction , 1994, The Lancet.

[14]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[15]  F. Epstein,et al.  Electrocardiographic Findings Among the Adult Population of a Total Natural Community, Tecumseh, Michigan , 1965, Circulation.

[16]  A R Feinstein,et al.  Risk for systemic embolization of atrial fibrillation without mitral stenosis. , 1990, The American journal of cardiology.

[17]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[18]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[19]  F. Silverstone,et al.  Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. , 1991, Archives of internal medicine.

[20]  S. Connolly,et al.  Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. , 1991, Circulation.

[21]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[22]  G. Albers,et al.  Atrial fibrillation and stroke. Three new studies, three remaining questions. , 1994, Archives of internal medicine.

[23]  J. Milne,et al.  Prevalence of clinical and electrocardiographic evidence of ischaemic heart disease in the older population. , 1973, British heart journal.

[24]  D. Singer,et al.  Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. , 1991, The American journal of medicine.

[25]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[26]  G. MacGregor,et al.  Survey of use of anticoagulation in patients with atrial fibrillation. , 1993, BMJ.

[27]  P. T. Onundarson,et al.  Chronic atrial fibrillation--epidemiologic features and 14 year follow-up: a case control study. , 1987, European heart journal.

[28]  B. Norrving,et al.  Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. , 1992, BMJ.

[29]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.